NCT00615433 Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia Status COMPLETED Phase PHASE3
NCT00611806 Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia Status COMPLETED Phase PHASE4
NCT00604279 A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia Status COMPLETED Phase PHASE3
NCT00601224 Social Cognition and Interaction Training for Improving Social Functioning in People With Schizophrenia Status COMPLETED Phase PHASE1
NCT00595504 Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia Status COMPLETED Phase PHASE4
NCT00591318 A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis Status TERMINATED Phase PHASE1/PHASE2
NCT00590577 Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia Status COMPLETED Phase PHASE3
NCT00589914 Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia Status COMPLETED Phase PHASE3
NCT00588731 Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia Status COMPLETED Phase PHASE2
NCT00585390 Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia Status COMPLETED Phase PHASE2/PHASE3
NCT00584519 Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight Status COMPLETED Phase N/A
NCT00581932 Relationship Between Neurotransmitter Receptor Polymorphisms, Plasma Concentrations and Clinical Response to Clozapine Status COMPLETED Phase N/A
NCT00580125 Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia Status COMPLETED Phase PHASE2